|
Post by babaoriley on Nov 10, 2017 19:24:46 GMT -5
Didn't we also have one during the CMA show?
|
|
|
Post by sportsrancho on Nov 10, 2017 19:28:59 GMT -5
Didn't we also have one during the CMA show? Yes
|
|
|
Post by kball on Nov 10, 2017 20:58:07 GMT -5
Any word whether we may see some during Winter Olympics in 3 months?
I haven't seen one since the diabetes show. Hoping to see some on basketball telecasts soon
And SURVIVOR. And THIS IS US (Couple of my favorites)
|
|
|
Post by mnkdnewbie on Nov 10, 2017 21:00:48 GMT -5
On the cma? I just ran through the dvr twice and didn't see afrezza on the cmas, must not be targeting the Baltimore metro area.
|
|
|
Post by sportsrancho on Nov 11, 2017 6:26:30 GMT -5
Any word whether we may see some during Winter Olympics in 3 months? I haven't seen one since the diabetes show. Hoping to see some on basketball telecasts soon And SURVIVOR. And THIS IS US (Couple of my favorites) I haven’t seen, THIS IS US, But my clients are all crazy about the show!
|
|
|
Post by kball on Nov 11, 2017 9:40:04 GMT -5
Any word whether we may see some during Winter Olympics in 3 months? I haven't seen one since the diabetes show. Hoping to see some on basketball telecasts soon And SURVIVOR. And THIS IS US (Couple of my favorites) I haven’t seen, THIS IS US, But my clients are all crazy about the show!Amazing writing, acting and story lines. Best network drama show in a while that i can remember. If i had one complaint its too many commercials in the back half of every episode. (Which may be good for a Mannkind commercial, though maybe in the front half it gets more attention as there are fewer.)
|
|
|
Post by peppy on Nov 12, 2017 6:28:29 GMT -5
I still say, you tube. run the commercial on you tube prior to the video. other pharma is.
|
|
|
Post by mnholdem on Nov 12, 2017 6:56:13 GMT -5
|
|
|
Post by pguererro on Nov 12, 2017 8:23:59 GMT -5
There are around 12 large markets that Afrezza is currently airing. These are markets that Afrezza has gained nice traction. It’s easier to push a large bolder if it’s already moving. There has already been response from the TV ads however remember it can take 3~6 months for a pwd to see their endo unless they already have a scheduled appointment. Much less for those type 2’s still being managed by their internists and family practice docs.
|
|
|
Post by pantaloons on Nov 12, 2017 8:33:42 GMT -5
There are around 12 large markets that Afrezza is currently airing. These are markets that Afrezza has gained nice traction. It’s easier to push a large bolder if it’s already moving. There has already been response from the TV ads however remember it can take 3~6 months for a pwd to see their endo unless they already have a scheduled appointment. Much less for those type 2’s still being managed by their internists and family practice docs. Is there data that provides insight on what percentage of PWD (Type I vs. Type II) get their insulin prescriptions from PCP vs. Endo's? Can PWD request a change of insulin from their PCP and titrate without the initial direct guidance of the Endo? On another note, how much Afrezza composes a typical PWD's prandial insulin usage? That is, for those using Afrezza, does it typically compose ~25%, 50%, 75%, 100%, etc. of their overall prandial insulin usage?
|
|
|
Post by sportsrancho on Nov 12, 2017 9:06:57 GMT -5
The T2’s that I know got their scripts from PCP not Endo’s. The kids have had both a PCP and a pediatric Endo.
I just saw a Dexcom commercial. My first. Fox News. They were explaining about how to use it and your A-1 C. It was targeted at type2’s.
|
|
|
Post by pguererro on Nov 12, 2017 9:08:12 GMT -5
The rapid acting market volume is still dominated by Endo’s....maybe 80%. Generally an internist/FP is comfortable loading patient up with basal. Probably 50% are comfortable starting a patient on bolus, however with GLP 1 and SGLT 2 they can now wait longer to initiate meal time. For those I/FP theyll manage pwd until low doses of bolus need to be intensified. At that point they generally refer to an Endo. Once referred to an Endo an I/FP would probably not change insulin regimen. They like to transfer risk to “specialist”. % of insulin basal vs bolus for pwd depends on whether Type 1 or 2. A Type 1 generally uses a more balanced ratio say maybe 50/50, however a Type 2 may look more like 70/30 basal/bolus. It varies tremendously patient to patient.
With the insulin market being 90% Type 2 Internists/FP will be crucial to the success of Afrezza. Stubborn Endos are coming around and DTC should spark questions in the Endo and I/FP offices. Both segments are being heavily targeted by Mannkind. Mannkind knows the I/FP offices that write rapid acting.
|
|
|
Post by sayhey24 on Nov 12, 2017 16:58:30 GMT -5
The rapid acting market volume is still dominated by Endo’s....maybe 80%. Generally an internist/FP is comfortable loading patient up with basal. Probably 50% are comfortable starting a patient on bolus, however with GLP 1 and SGLT 2 they can now wait longer to initiate meal time. For those I/FP theyll manage pwd until low doses of bolus need to be intensified. At that point they generally refer to an Endo. Once referred to an Endo an I/FP would probably not change insulin regimen. They like to transfer risk to “specialist”. % of insulin basal vs bolus for pwd depends on whether Type 1 or 2. A Type 1 generally uses a more balanced ratio say maybe 50/50, however a Type 2 may look more like 70/30 basal/bolus. It varies tremendously patient to patient. With the insulin market being 90% Type 2 Internists/FP will be crucial to the success of Afrezza. Stubborn Endos are coming around and DTC should spark questions in the Endo and I/FP offices. Both segments are being heavily targeted by Mannkind. Mannkind knows the I/FP offices that write rapid acting. What you are describing is the hill MNKD needs to climb and defeat. afrezza should be the first thing prescribed not the last. If the PCP did this there would be no need for the Endo, Internist or anyone else. If caught early enough many PWDs would probably not need any medication after 6 months if maintained in a near non-diabetic range. The target long-term market for afrezza should be the PCPs. Short-term its clearly anyone willing to write a script.
|
|
|
Post by sayhey24 on Nov 12, 2017 17:04:20 GMT -5
The T2’s that I know got their scripts from PCP not Endo’s. The kids have had both a PCP and a pediatric Endo. I just saw a Dexcom commercial. My first. Fox News. They were explaining about how to use it and your A-1 C. It was targeted at type2’s. T2s, really? Not many T2s have CGMs today and few will get insurance to pay for it. Dexcom maybe feeling the up coming challenge from the Libre which will run about $20 a week for the sensor and will be at most large pharmacies, in another month maybe even Costco.
|
|
|
Post by sportsrancho on Nov 12, 2017 17:55:25 GMT -5
The T2’s that I know got their scripts from PCP not Endo’s. The kids have had both a PCP and a pediatric Endo. I just saw a Dexcom commercial. My first. Fox News. They were explaining about how to use it and your A-1 C. It was targeted at type2’s. T2s, really? Not many T2s have CGMs today and few will get insurance to pay for it. Dexcom maybe feeling the up coming challenge from the Libre which will run about $20 a week for the sensor and will be at most large pharmacies, in another month maybe even Costco. www.ispot.tv/ad/wjaA/dexcom-g5-mobile-improve-your-quality-of-lifeNow after watching again they may be over 65 T1’s...
|
|